Is $99 Compounded Semaglutide Real? We Verified Every Provider at the Floor Price

The cheapest compounded semaglutide on the cash-pay telehealth market as of 2026-05-20 sits at $49 per month, advertised by one provider we track. That's only 28% of the market median of $175, and a small fraction of brand-name Wegovycash-pay pricing. We verified each floor-price provider against our pricing index and pharmacy database to answer one question: is the floor price legitimate, or are there hidden gotchas?

The market context: where $49 sits in the distribution

Across the 152 telehealth providers we track that offer compounded semaglutide, the price distribution looks like this:

At $49, the floor price is 72% below the median provider and 84% below the 90th percentile. That kind of dispersion is unusual in any consumer drug market — it tells you the providers at the floor are playing a very different pricing game than the providers above it.

The provider at $49/month

Here's every provider we track that currently advertises compounded semaglutide at the $49/month floor, plus the editorial verification we've completed for each:

• Enhance MD — $49/month · WLR score 8.7/10 · ships to 39 states. Best for: lab-monitored compounded GLP-1 with mandatory video visit.

The next tier: providers within $10 of the floor

Just above the absolute floor sit a small group of providers within $10/month of the cheapest tier. If the floor providers don't ship to your state or don't carry your dose, these are the next-cheapest legitimate options:

• Bliv — $58/month

What floor pricing actually buys you (and what it doesn't)

A $49/month advertised price almost always refers to the starting dose of compounded semaglutide (typically 0.25mg weekly), not the maintenance dose most patients end up at after titration (1.0mg or 1.7mg weekly). When you actually progress through your dose schedule, the monthly cost on most floor-priced providers rises to match the higher-dose tier on their pricing page. We track maintenance pricing on the same price tracker, and our 12-month price movement investigation documents how that floor has shifted over time.

Things the floor price does include for the verified providers above: a synchronous or asynchronous medical consultation, a prescription written by a licensed clinician, the compounded medication itself, basic patient support, and shipping. For a closer look at how the compounded vial actually compares to the brand-name pen on a day-to-day level, see our Wegovy pen vs compounded vial breakdown.

Things the floor price typically does not include: labs, insurance billing, syringes (some providers; check the per-provider page), expedited shipping, after-hours support, and dose changes that fall outside the manufacturer's standard titration. None of these are deal-breakers, but they're worth knowing about before you commit.

Red flags that mean the cheapest price is too good

Not every $49/month listing is legitimate. We verified that the providers above are licensed and shipping real product, but elsewhere on the open internet there are sub-floor offers that come with serious problems. Watch for:

• No US-based prescriber. Compounded semaglutide requires a valid prescription from a clinician licensed in your state. Sites that skip the consultation step or that have a prescriber outside the US are violating federal law and your medication is not legitimate compounded product.
• No named compounding pharmacy. Reputable providers name their fulfillment pharmacy on their website or in their consent forms. If you can't find out who is actually compounding your medication, that's a problem.
• Salt forms. Multiple FDA warning letters cite providers using semaglutide sodium or semaglutide acetate (salt forms) instead of base semaglutide. Salt forms are not the same active ingredient as the molecule used in approved drugs and have not been evaluated for safety — our compounded semaglutide bioequivalence investigation walks through what “same molecule” actually means in this context. See our FDA warning letter investigation for the full pattern.
• Prices below the legitimate floor. Anything dramatically cheaper than the $49/month tier documented here should be treated as suspicious until proven otherwise.

Methodology

Every price in this article is computed at render time from the Weight Loss Rankings provider dataset. When new providers are added or existing providers change their pricing, this article updates automatically — the prose adjusts to reflect the new floor, the new median, and any new verified providers tied at the floor.

The pricing dataset itself is verified directly against each provider's public website on a continuous basis by our editorial team. The verification process and data sources are documented at our methodology page. The full provider list and their pricing rows are available on the live price tracker.

Last data refresh: 2026-05-20.

What about generic semaglutide?

A common reader question: if compounded semaglutide is so much cheaper than brand Wegovy, when will an FDA-approved generic semaglutide arrive and make this whole compounded debate moot? Short answer: not for years. Composition-of-matter patents on semaglutide are widely modeled to expire in the early 2030s, with the practical first-generic launch window estimated at 2031-2033 and subject to paragraph-IV litigation, pediatric exclusivity, and ANDA settlement timing. The two FDA-approved generic GLP-1s already on the US market are both liraglutide (Hikma referencing Victoza, December 2024; Teva referencing Saxenda, August 2025) — not semaglutide. For the full per-drug patent-cliff timeline including Wegovy, Ozempic, Mounjaro, Zepbound, Foundayo, and Trulicity, see our GLP-1 generic timeline & patent cliff tracker.

Is SlimDownRx, Mochi Health, or lozempic a real GLP-1 provider?

SlimDownRx and Mochi Health are real US-based telehealth providers that prescribe compounded semaglutide and tirzepatide through 503A partner pharmacies — both are tracked in our verified provider directory. “Lozempic” is NOT a brand name; it is a common misspelling of Ozempic (semaglutide for type 2 diabetes, Novo Nordisk). For Ozempic-related cash-pay options see our Wegovy + Ozempic cash-pay channel guide.

For verified provider comparisons including Mochi pricing and SlimDownRx pricing, the all-in monthly-cost table at the top of this article reflects every tracked 503A provider in our database. The full provider directory with primary-source verification dates lives at /providers.

Related research

• Compounded tirzepatide vs compounded semaglutide — side-by-side comparison of the two molecules, fridge life and beyond-use date, regulatory status post-Feb 2025, common additives (B12, NAD+), and the SURMOUNT-5 head-to-head efficacy data
• GLP-1 pricing index — current cash-pay prices across brand-name and compounded channels, updated monthly
• Compounded semaglutide bioequivalence — what the regulatory rules do and don't guarantee about the compounded vial in your fridge
• Pharmacy Legitimacy Lookup tool — verify any compounding pharmacy before purchasing. Checks FDA warning letters, openFDA drug recalls, state pharmacy license status (Texas + Illinois databases), and 503B outsourcing facility registration. Five primary-source disclosure rows per query, no AI score.